What are Convalescent plasma drugs?

Convalescent plasma drugs are pharmacologic agents that share a common mechanism (typically targeting SARS-CoV-2 spike protein and other viral antigens). 1 are currently marketed, with 2 more in clinical development.

What are the marketed Convalescent plasma drugs?

Marketed Convalescent plasma drugs include CCP.

Convalescent plasma

1 marketed 2 in Phase 3

This page covers all Convalescent plasma drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SARS-CoV-2 spike protein and other viral antigens, Influenza virus surface antigens (hemagglutinin, neuraminidase).

Targets

SARS-CoV-2 spike protein and other viral antigens · Influenza virus surface antigens (hemagglutinin, neuraminidase)

Marketed (1)

CCP · Metro Infectious Disease Consultants · Infectious Disease
CCP is a convalescent plasma product that provides passive immunotherapy through antibodies from recovered COVID-19 patients to treat active SARS-CoV-2 infection.

Phase 3 pipeline (2)

Low-titer anti-influenza plasma · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease
Low-titer anti-influenza plasma provides passive immunotherapy by transferring antibodies from donors with prior influenza exposure to neutralize circulating influenza virus in infected patients.
High-titer anti-influenza plasma · National Institute of Allergy and Infectious Diseases (NIAID) · Infectious Disease / Virology
High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection.